We are live on ! Find out more
BCM

Boxer Capital Management Portfolio holdings

AUM $762M
1-Year Est. Return 1,125.36%
This Fund
S&P 500
This Quarter Est. Return
-6.27%
1 Year Est. Return
+1,125.36%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$332M
AUM Growth
-$842M
Cap. Flow
-$767M
Cap. Flow %
-230.79%
Top 10 Hldgs %
72.35%
Holding
62
New
2
Increased
2
Reduced
10
Closed
34

Top Buys

Rank Stock Value
1
SLDB icon
Solid Biosciences
SLDB
+$5.31M
2
DNLI icon
Denali Therapeutics
DNLI
+$4.79M
3
PRLD icon
Prelude Therapeutics
PRLD
+$373K
4
KOD icon
Kodiak Sciences
KOD
+$190K

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$124M
2
RVMD icon
Revolution Medicines
RVMD
+$120M
3
NUVL
Nuvalent
NUVL
+$52.4M
4
MRUS
Merus
MRUS
+$52.3M
5
AXSM icon
Axsome Therapeutics
AXSM
+$39.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLYM
26
Climb Bio
CLYM
$719M
$177K 0.05%
145,000
-2,458,190
-94% -$3.99M
NUVB.WS
27
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$85.3K 0.03%
266,666
– –
SRZNW icon
28
Surrozen Inc Warrant
SRZNW
$2K ﹤0.01%
66,666
– –
APGE icon
29
Apogee Therapeutics
APGE
$10.1B
– –
-86,000
Closed -$3.9M
ARVN icon
30
Arvinas
ARVN
$581M
– –
-1,058,614
Closed -$20.3M
AXSM icon
31
Axsome Therapeutics
AXSM
$10.9B
– –
-470,000
Closed -$39.8M
BCAB icon
32
BioAtla
BCAB
$5.56M
– –
-13,727
Closed -$406K
BDTX icon
33
Black Diamond Therapeutics
BDTX
$102M
– –
-506,000
Closed -$1.08M
CGEM icon
34
Cullinan Oncology
CGEM
$1.08B
– –
-907,895
Closed -$11.1M
DBVT
35
DBV Technologies
DBVT
$811M
– –
-50,000
Closed -$155K
GERN icon
36
Geron
GERN
$860M
– –
-6,000,000
Closed -$21.2M
GPCR icon
37
Structure Therapeutics
GPCR
$3.53B
– –
-500,000
Closed -$13.6M
IMVT icon
38
Immunovant
IMVT
$8.08B
– –
-825,000
Closed -$20.4M
IOVA icon
39
Iovance Biotherapeutics
IOVA
$1.95B
– –
-750,000
Closed -$5.55M
ITOS
40
DELISTED
iTeos Therapeutics
ITOS
– –
-946,915
Closed -$7.27M
JSPR icon
41
Jasper Therapeutics
JSPR
$22.1M
– –
-350,000
Closed -$7.48M
KALV
42
DELISTED
KalVista Pharmaceuticals
KALV
– –
-1,590,000
Closed -$13.5M
KROS icon
43
Keros Therapeutics
KROS
$203M
– –
-250,000
Closed -$3.96M
MIST icon
44
Milestone Pharmaceuticals
MIST
$146M
– –
-309,007
Closed -$729K
MRSN
45
DELISTED
Mersana Therapeutics
MRSN
– –
-105,400
Closed -$3.77M
OBIO icon
46
Orchestra BioMed
OBIO
$256M
– –
-238,193
Closed -$953K
OLMA icon
47
Olema Pharmaceuticals
OLMA
$1.03B
– –
-650,000
Closed -$3.79M
RCKT icon
48
Rocket Pharmaceuticals
RCKT
$376M
– –
-1,466,051
Closed -$18.4M
RCUS icon
49
Arcus Biosciences
RCUS
$3.62B
– –
-1,602,200
Closed -$23.9M
RLAY icon
50
Relay Therapeutics
RLAY
$4.26B
– –
-536,132
Closed -$2.21M
1
2
3

Similar funds

GWM
Gibbs Wealth Management Alpharetta, Georgia $762M AUM 18.55% 1-Year Est. Return
TI
Think Investments San Francisco, California $762M AUM 33.1% 1-Year Est. Return
CFS
Cannon Financial Strategists Athens, Georgia $761M AUM 18.73% 1-Year Est. Return
PMWMG
Parr McKnight Wealth Management Group Minneapolis, Minnesota $763M AUM 13.49% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
CCIP
Camrose Capital Investment Partners London, United Kingdom $764M AUM 0.9% 1-Year Est. Return
FA
Fiducient Advisors Chicago, Illinois $765M AUM 12.73% 1-Year Est. Return

Boxer Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Boxer Capital Management held 62 positions worth $332M, down 72% from $1.17B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Boxer Capital Management withdrew a net $767M in Q1 2025, closing 34 positions and reducing 10 holdings. Its most notable exit was SpringWorks Therapeutics, an estimated $124M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Boxer Capital Management opened a new position in Solid Biosciences worth $4.59M.

  • Boxer Capital Management's largest Q1 2025 buy was Solid Biosciences: 1,240,700 shares worth $4.59M.
  • Boxer Capital Management added most to Prelude Therapeutics in Q1 2025, an estimated $373K increase.
  • Boxer Capital Management's biggest Q1 2025 reduction was Revolution Medicines, cutting an estimated $120M.
  • Boxer Capital Management fully exited SpringWorks Therapeutics in Q1 2025, selling an estimated $124M.
  • Boxer Capital Management's ten largest holdings make up 72% of its $332M portfolio in Q1 2025.
  • Boxer Capital Management opened 2 new positions and closed 34 in Q1 2025.
  • Boxer Capital Management's portfolio value fell 72% quarter-over-quarter to $332M.

Based on Boxer Capital Management's 13F filing for Q1 2025, filed 15 May 2025.